Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study.

Kumar D, Selwyn Selva; Somarkutty, Nishi; Prasad D, Jayavelu Hariram; Gautam, Priyanka; Nagaraj, Veerasamy; Karthik, Rajiv; Vanjare, Harshad Arvind; Appaswamy, Prabhakar Thirumal et al. · Clin Infect Dis · 2026

retrospective_cohort · Level III

Where this comes from

Record sourced from PubMed, PMID 41856917.
Also identified by DOI 10.1093/cid/ciaf573.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

We evaluated low-dose infliximab (5 mg/kg) as adjunctive therapy in 20 patients with severe central nervous system tuberculosis. At 3 months, 60% achieved disability-free survival (modified Rankin Scale ≤ 2), and 75% showed clinically meaningful improvement. Our outcomes matched reports of high-dose infliximab. Randomized trials to optimize dosing are needed.

Read the full text

View on PubMed · Publisher (DOI)